A placebo-controlled trial of acetyl-l-carnitine and α-lipoic acid in the treatment of bipolar depression

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 627-635

  Brennan, Brian P ^a   Jensen, John Eric ^a   Hudson, James I ^a   Coit, Caitlin E ^a   Beaulieu, Ashley ^a   Pope, Harrison G ^a   Renshaw, Perry F ^a   Cohen, Bruce M ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE PHOSPHATE; LEVACECARNINE; NUCLEOSIDE TRIPHOSPHATE; PLACEBO; THIOCTIC ACID;

ABDOMINAL PAIN; ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; BRAIN LEVEL; BRAIN METABOLISM; BRAIN MITOCHONDRION; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPEPSIA; ENERGY METABOLISM; FEMALE; HUMAN; LIVER FUNCTION TEST; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OCCIPITAL CORTEX; PARIETAL CORTEX; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; THORAX PAIN; THREE DIMENSIONAL IMAGING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINE ODOR;

ACETYLCARNITINE; ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; BRAIN; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; ENERGY METABOLISM; FEMALE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MITOCHONDRIA; PHOSPHOCREATINE; PSYCHIATRIC STATUS RATING SCALES; THIOCTIC ACID; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883750131     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31829a83f5     Document Type: Article

References (53)

1. Post RM. The impact of bipolar depression. J Clin Psychiatry. 2005;66(Suppl 5):5-10
2. Keck PE Jr, Nelson EB, McElroy SL. Advances in the pharmacologic treatment of bipolar depression. Biol Psychiatry. 2003;53:671-679
3. Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: Criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord. 2003;5:85-97
4. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1-93
5. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711-1722
6. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000;2:180-190
7. Peters A, Schweiger U, Pellerin L, et al. The selfish brain: Competition for energy resources. Neurosci Biobehav Rev. 2004;28:143-180
8. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: Evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10:900-919
9. Konradi C, Eaton M, MacDonald ML, et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300-308
10. Naydenov AV, MacDonald ML, Öngür D, et al. Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch Gen Psychiatry. 2007;64:555-564
11. Cataldo AM, McPhie DL, Lange NT, et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol. 2010;177:575-585
12. Regenold WT, Phatak P, Marano CM, et al. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: Implications for the mitochondrial dysfunction hypothesis. Biol Psychiatry. 2009;65:489-494
13. Aureli T, Di Cocco ME, Puccetti C, et al. Acetyl-L-carnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain. Brain Res. 1998;796:75-81
14. Capecchi PL, Laghi Pasini F, Quartarolo E, et al. Carnitines increase plasma levels of adenosine and ATP in humans. Vasc Med. 1997;2:77-81
15. Jeulin C, Soufir JC, Marson J, et al. [Acetylcarnitine and spermatozoa: Relationship with epididymal maturation and motility in the boar and man]. Reprod Nutr Dev. 1988;28:1317-1327
16. Rao KV, Mawal YR, Qureshi IA. Progressive decrease of cerebral cytochrome C oxidase activity in sparse-fur mice: Role of acetyl-L-carnitine in restoring the ammonia-induced cerebral energy depletion. Neurosci Lett. 1997;224:83-86
17. Rosenthal RE, Williams R, Bogaert YE, et al. Prevention of postischemic canine neurological injury through potentiation of brain energy metabolism by acetyl-L-carnitine. Stroke. 1992;23:1312-1317; discussion 1317-1318
18. Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res. 1990;10:355-360
19. Fulgente T, Onofrj M, Del Re ML, et al. Laevo-Acetylcarnitine (Nicetile) treatment of senile depression. Clin Trials J. 1990;27:155-163
20. Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-Acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res. 1990;16:101-106
21. Gecele M, Francesetti G, Meluzzi A. Acetyl-L-carnitine in aged subjects with major depression: Clinical efficacy and effects on the circadian rhythm of cortisol. Dementia. 1991;2:333-337
22. Nasca D, Zurria G, Aguglia E. Action of acetyl-L-carnitine in association with mianserine on depressed old people. New Trends Clin Neuropharmacol. 1989;3:225-230
23. Pettegrew JW, Levine J, Gershon S, et al. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: Preliminary results. Bipolar Disord. 2002;4:61-66
24. Tempesta E, Casella L, Pirrongelli C, et al. L-Acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res. 1987;13:417-423
25. Villardita C, Smirni P, Vecchio I. Acetyl-L-carnitine in depressed geriatric patients. Eur Rev Med Pharmacol Sci. 1983;6:1-12
26. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol. 2006;16:281-287
27. Martinotti G, Andreoli S, Reina D, et al. Acetyl-L-carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:953-958
28. Hagen TM, Liu J, Lykkesfeldt J, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A. 2002;99:1870-1875
29. Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R-Alpha-lipoic acid. Proc Natl Acad Sci U S A. 2002;99:2356-2361
30. Liu J, Killilea DW, Ames BN. Age-Associated mitochondrial oxidative decay: Improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-Alpha-lipoic acid. Proc Natl Acad Sci U S A. 2002;99:1876-1881
31. Tarnopolsky MA. The mitochondrial cocktail: Rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev. 2008;60:1561-1567
32. Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-250
33. Parnetti L, Gaiti A, Mecocci P, et al. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol. 1992;42:89-93
34. Öngür D, Jensen JE, Prescot AP, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008;64:718-726
35. Brennan BP, Hudson JI, Jensen JE, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology. 2010;35:834-846
36. Thal LJ, Carta A, Clarke WR, et al. A L-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996;47:705-711
37. Ziegler D Hanefeld M Ruhnau KJ et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid 7-month Multicenter Randomized Controlled Trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid In Diabetic Neuropathy. Diabetes Care. 1999;221296-1301
38. Gleiter CH, Schug BS, Hermann R, et al. Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacol. 1996;50:513-514
39. Jensen JE, Drost DJ, Menon RS, et al. In vivo brain (31)P-MRS: Measuring the phospholipid resonances at 4 Tesla from small voxels. NMR Biomed. 2002;15:338-347
40. Petroff OA, Prichard JW, Behar KL, et al. Cerebral intracellular pH by 31P nuclear magnetic resonance spectroscopy. Neurology. 1985;35:781-788
41. Berk M, Copolov DL, Dean O, et al. N-Acetyl cysteine for depressive symptoms in bipolar disorderYa double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468-475
42. Judd LL, Schettler PJ, Akiskal HS, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry. 2008;65:386-394
43. Berk M, Dean O, Cotton SM, et al. The efficacy of N-Acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. J Affect Disord. 2011;135:389-394
44. Miyake N, Skinbjerg M, Easwaramoorthy B, et al. Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-Acetylcysteine challenge. Biol Psychiatry. 2011;69:822-824
45. Forester BP, Zuo CS, Ravichandran C, et al. Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol. 2012;25:43-50
46. Al-Majed AA, Sayed-Ahmed MM, Al-Omar FA, et al. Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus. Clin Exp Pharmacol Physiol. 2006;33:725-733
47. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004;1033:30-41
48. Hoppel C. The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis. 2003;41:S4-12
49. Aureli T, Miccheli A, Ricciolini R, et al. Aging brain: Effect of acetyl-L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy. Brain Res. 1990;526:108-112
50. Forester BP, Berlow YA, Harper DG, et al. Age-related changes in brain energetics and phospholipid metabolism. NMR Biomed. 2010;23:242-250
51. Mancinelli A, Longo A, Shanahan K, et al. Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther. 1995;274:1122-1128
52. Harper P, Elwin CE, Cederblad G. Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. Eur J Clin Pharmacol. 1988;35:555-562
53. Sahajwalla CG, Helton ED, Purich ED, et al. Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution in healthy adult male volunteers. J Pharm Sci. 1995;84:627-633